home / stock / uncy / uncy news

UNCY News and Press, Unicycive Therapeutics Inc. From 11/13/23

Stock Information
Company Name: Unicycive Therapeutics Inc.
Stock Symbol: UNCY
Market: NASDAQ
Website: unicycive.com
Menu
UNCY UNCY Quote UNCY Short UNCY News UNCY Articles UNCY Message Board
Get UNCY Alerts

News, Short Squeeze, Breakout and More Instantly...
UNCY - Expected US Company Earnings on Monday, November 13th, 2023

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
UNCY - Expected earnings - Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc. (UNCY) is expected to report $-0.13 for Q3 2023

UNCY - Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or...

UNCY - Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the appointment of Sara ...
UNCY - Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...

UNCY - Unicycive Therapeutics GAAP EPS of $0.29 beats by $0.57

2023-08-15 10:30:37 ET Unicycive Therapeutics press release ( NASDAQ: UNCY ): Q2 GAAP EPS of $0.29 beats by $0.57 . R&D expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.9 million for the same period in 2022. As of June 30, 2023, ca...

UNCY - Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA Expected in Fall 2023 for OLC Program UNI-494 Phase 1 Trial Progressing as Planned with ...
UNCY - CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies previously announced it would air interviews with 60 Degrees Pharmaceuticals, Inc. and Unicycive Therapeutics, Inc. (Nasdaq:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). T...

UNCY - 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). Bloomberg TV...

UNCY - Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D.,...
Previous 10 Next 10